Published in Cancer Weekly, June 3rd, 1996
In patients with advanced cancer and over-expression of EGFr (EGFr-positive cancers), seven out of a total of 17 patients demonstrated stable disease after four weeks, and subsequently received additional treatments on a weekly basis for another eight weeks. No major toxicities were noted in this study.
"The results from our Phase Ib/IIa...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.